

Documents

Affendi, N.A.N.M.^{a b}, Ooi, C.J.^c, Hilmi, I.N.^a

Accelerated ustekinumab dosing as rescue therapy in acute severe ulcerative colitis
(2022) *Journal of Gastrointestinal and Liver Diseases*, 31 (4), pp. 478-479. Cited 2 times.

DOI: 10.15403/jgld-4599

^a Division of Gastroenterology and Hepatology, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

^b Division of Gastroenterology and Hepatology, Faculty of Medicine, International Islamic University of Malaysia, Kuantan, Malaysia

^c Duke-NUS Medical School, Gleneagles Medical Centre, Singapore

Index Keywords

albumin, C reactive

protein, cyclosporine, hemoglobin, hydrocortisone, infliximab, mesalazine, prednisolone, steroid, ustekinumab, gastrointestinal agent, infliximab, ustekinumab; abdominal distension, acute severe ulcerative colitis, aged, bloody diarrhea, case report, chronic obstructive lung disease, clinical article, colonoscopy, computer assisted tomography, congestive heart failure, diabetes mellitus, fever, human, inflammation, ischemic heart disease, lethargy, Letter, loading drug dose, male, polyp, scar formation, sigmoidoscopy, ulcer, ulcerative colitis, treatment outcome, ulcerative colitis; Colitis, Ulcerative, Gastrointestinal Agents, Humans, Infliximab, Treatment Outcome, Ustekinumab

Chemicals/CAS

C reactive protein, 9007-41-4; cyclosporine, 59865-13-3, 63798-73-2, 79217-60-0; hemoglobin, 9008-02-0; hydrocortisone, 50-23-7; infliximab, 170277-31-3; mesalazine, 89-57-6; prednisolone, 50-24-8; ustekinumab, 815610-63-0, 949907-93-1; Gastrointestinal Agents; Infliximab; Ustekinumab

References

- Laharie, D, Bourreille, A, Branche, J
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial
(2012) *Lancet*, 380, pp. 1909-1915.
- Wang, Z, Verstockt, B, Sabino, J
Population pharmacokinetic-pharmacodynamic model-based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease
(2022) *Br J Clin Pharmacol*, 88, pp. 323-335.
- Storan, D, Doherty, GA, Cullen, G.
Ustekinumab 90 mg Every 2 Weeks for the Treatment of Inflammatory Bowel Disease
(2021) *Clin Gastroenterol Hepatol*, 19, p. 1502.

Correspondence Address

Hilmi I.N.; Division of Gastroenterology and Hepatology, Malaysia; email: Ida.hilmi@gmail.com

Publisher: Romanian Society of Gastroenterology

ISSN: 18418724

PubMed ID: 36535053

Language of Original Document: English

Abbreviated Source Title: J. Gastrointest. Liver Dis.

2-s2.0-85144285119

Document Type: Letter

Publication Stage: Final

Source: Scopus

ELSEVIER

Copyright © 2023 Elsevier B.V. All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

 **RELX Group™**